0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Commentary | Clinician's Corner

The Incidentalome:  A Threat to Genomic Medicine

Isaac S. Kohane, MD, PhD; Daniel R. Masys, MD; Russ B. Altman, MD, PhD
JAMA. 2006;296(2):212-215. doi:10.1001/jama.296.2.212.
Text Size: A A A
Published online

Extract

Genomic medicine is poised to offer a broad array of new genome-scale screening tests. However, these tests may lead to a phenomenon in which multiple abnormal genomic findings are discovered, analogous to the “incidentalomas” that are often discovered in radiological studies. If practitioners pursue these unexpected genomic findings without thought, there may be disastrous consequences. First, physicians will be overwhelmed by the complexity of pursuing unexpected genomic measurements. Second, patients will be subjected to unnecessary follow-up tests, causing additional morbidity. Third, the cost of genomic medicine will increase substantially with little benefit to patients or physicians (but with great financial benefits to the genomic testing industry), thus throwing the overall societal benefit of genome-based medicine into question. In this article, we discuss the basis for these concerns and suggest several steps that can be taken to help avoid these substantive risks to the practice of genomically personalized medicine.

Figures in this Article

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Figure. Percentage of Total Population With a False-Positive Test Result
Graphic Jump Location

As the number of tests increases to 10 000, the fraction of the population that has a false-positive test result increases to more than 60%. Any large-scale genomic panel is therefore likely to routinely report false-positive results. The data for this figure were generated by running a simulation in which a population of 100 000 was tested with 1 through 10 000 tests, each with a sensitivity of 100% and a false-positive rate of 0.01%. That is, 10 individuals with false-positive tests were randomly selected from the population for each test. Because some individuals could be selected more than once with a larger panel of tests, the increase in the number of individuals with false-positive test results is less than linear.

Tables

References

Letters

CME


You need to register in order to view this quiz.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 147

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
Jobs
JAMAevidence.com


Genome

brightcove.createExperiences();